BR0115646A - Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente - Google Patents

Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente

Info

Publication number
BR0115646A
BR0115646A BR0115646-2A BR0115646A BR0115646A BR 0115646 A BR0115646 A BR 0115646A BR 0115646 A BR0115646 A BR 0115646A BR 0115646 A BR0115646 A BR 0115646A
Authority
BR
Brazil
Prior art keywords
composition
nucleic acid
antigen
enhancing
interest
Prior art date
Application number
BR0115646-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Joel R Haynes
Joshua E Arrington
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of BR0115646A publication Critical patent/BR0115646A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0115646-2A 2000-11-27 2001-11-26 Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente BR0115646A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72431500A 2000-11-27 2000-11-27
PCT/US2001/043151 WO2003004055A2 (en) 2000-11-27 2001-11-26 Nucleic acid adjuvants

Publications (1)

Publication Number Publication Date
BR0115646A true BR0115646A (pt) 2005-12-13

Family

ID=24909936

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115646-2A BR0115646A (pt) 2000-11-27 2001-11-26 Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente

Country Status (16)

Country Link
EP (1) EP1379273B1 (enExample)
JP (1) JP4221289B2 (enExample)
KR (1) KR20040045391A (enExample)
CN (1) CN1317034C (enExample)
AT (1) ATE442858T1 (enExample)
AU (1) AU2001297988B2 (enExample)
BR (1) BR0115646A (enExample)
CA (1) CA2429708A1 (enExample)
DE (1) DE60139959D1 (enExample)
DK (1) DK1379273T3 (enExample)
ES (1) ES2332261T3 (enExample)
IL (2) IL156041A0 (enExample)
MX (1) MXPA03004638A (enExample)
NZ (1) NZ526175A (enExample)
PT (1) PT1379273E (enExample)
WO (1) WO2003004055A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101225395B1 (ko) 2003-10-10 2013-01-28 파우더젝트 백신, 인코포레이티드 핵산 구조물
BRPI0507579A (pt) 2004-02-11 2007-07-03 Angeletti P Ist Richerche Bio molécula de ácido nucleico, vetor, célula hospedeira, processo para expressar uma proteìna de fusão cea em uma célula hospedeira recombinante, proteìna de fusão cea purificada, método de prevenção ou tratamento de cáncer, plasmìdeo de vacina, e, método de tratamento de um mamìfero sofrendo de ou predisposto a um cáncer associados com cea
GB0507997D0 (en) * 2005-02-01 2005-05-25 Powderject Vaccines Inc Nucleic acid constructs
US8389686B2 (en) 2008-05-07 2013-03-05 Osaka University Noncovalent collagen crosslinking agent
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CA2848656C (en) 2010-09-15 2017-10-10 Randall J. Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
CN103060253A (zh) * 2013-01-24 2013-04-24 麻丽丹 霍乱弧菌ctxAB基因的质粒克隆菌株以及制备方法和应用
DK3139965T3 (da) 2014-05-07 2021-11-22 Applied Molecular Transport Inc Fusionsmolekyler afledt af cholix-toksin til oral indgivelse af biologisk aktive stoffer
EP4082558B1 (en) 2018-03-08 2023-08-23 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
KR20210110294A (ko) 2018-11-07 2021-09-07 어플라이드 몰레큘라 트랜스포트 인크. 통과세포외배출용 전달 구조체 및 관련 방법
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
GB9416663D0 (en) 1994-08-17 1994-10-12 Oxford Bioscience Limited Particle delivery
AU3703895A (en) 1994-10-24 1996-05-15 Oxford Biosciences Limited Particle delivery
GB9426379D0 (en) 1994-12-23 1995-03-01 Oxford Biosciences Ltd Particle delivery
US6056960A (en) * 1995-06-07 2000-05-02 Kaslow; Harvey R. Compositions exhibiting ADP-ribosyltransferase activity and methods for the preparation and use thereof
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization

Also Published As

Publication number Publication date
KR20040045391A (ko) 2004-06-01
EP1379273B1 (en) 2009-09-16
DE60139959D1 (de) 2009-10-29
CN1537013A (zh) 2004-10-13
MXPA03004638A (es) 2004-04-20
ES2332261T3 (es) 2010-02-01
WO2003004055A3 (en) 2003-11-20
JP2004536107A (ja) 2004-12-02
CN1317034C (zh) 2007-05-23
IL156041A0 (en) 2003-12-23
CA2429708A1 (en) 2003-01-16
ATE442858T1 (de) 2009-10-15
JP4221289B2 (ja) 2009-02-12
AU2001297988B2 (en) 2006-10-26
PT1379273E (pt) 2009-11-27
EP1379273A2 (en) 2004-01-14
NZ526175A (en) 2006-01-27
IL156041A (en) 2010-05-17
WO2003004055A2 (en) 2003-01-16
DK1379273T3 (da) 2009-11-09

Similar Documents

Publication Publication Date Title
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
DK1163008T3 (da) Anvendelse af trehalose til stabilisering af en flydende vaccine
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
DK1002110T3 (da) Immunsvar mod HPV-antigener fremkaldt af sammensætninger, som omfatter et HPV-antigen og et stressprotein eller en ekspressionsvektor i stand til at ekspressere disse proteiner
WO2002080851A3 (en) Chimeric vaccines
BR9906927A (pt) Proteìnas de neisseria meningitidis
MX339406B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
BR0115646A (pt) Composição, dispositivo de liberação de partìculas, uso de uma composição, e, método para intensificar uma resposta imune contra um antìgeno de interesse em um paciente
ATE293690T1 (de) Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
UA91180C2 (ru) Клетка бактерий mycobacterium bovis, которая является уреазодефицитной, и применение данной клетки для изготовления живой вакцины против туберкулеза
WO2005007673A3 (en) Immunogenic peptides
PT914437E (pt) Identificacao e clonagem de um antigenio micobacteriano correspondente a uma hemaglutinina de ligacao a heparina
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DE60025704D1 (de) Das goodpasture-antigen bindende protein
AU2001248822A1 (en) Gd3-mimetic peptides
DK1238086T3 (da) Vaccine til forögelse af immunreaktioner på herpes simplex virus
EP0972054A4 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
WO2003093298A3 (en) Immunogenic peptides
AP2368A (en) Novel expression vectors and uses thereof.
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
MXPA03010527A (es) Composicion de vacuna.
BR0013574A (pt) Antìgeno vacina de moraxella

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]